Percepta® GSC stratifies the risk of lung cancer to guide patient management when bronchoscopy is inconclusive
ABOUT PERCEPTA® GSC
What is the test?
Why is there a need to improve bronchoscopy diagnostic yield?
Inconclusive results can lead to uncertainty in next steps and delays in diagnosis.
What is Percepta GSC?
Percepta Genomic Sequencing Classifier (GSC) is uniquely positioned at the time of bronchoscopy to stratify the risk of primary lung cancer in the event of an inconclusive bronchoscopy.
How does Percepta GSC work?
During a bronchoscopy procedure, cells are collected from the right main stem bronchus using a cytology brush. In the event a bronchoscopy is inconclusive you may order Percepta GSC.
Smoking can cause lasting changes to the genes inside the cells in your airway.
The Percepta GSC test looks for and analyzes these genomic changes.
The Percepta GSC results stratify the risk of primary lung cancer to guide patient management.
Watch brief overview of the Percepta GSC test
Learn how to stratify the risk of primary lung cancer to help guide patient management.
Who is a good candidate for Percepta GSC?
Inconclusive bronchosopy
Current or former smokers and over 21 years of age
No concurrent or prior cancer
Percepta GSC is uniquely positioned at the time of bronchoscopy to stratify the risk of primary lung cancer to guide patient management.
Percepta GSC stratifies the risk of primary lung cancer across all pre-test groups when bronchoscopy is inconclusive.
Sample collection and ordering
Collect sample at the start of bronchoscopy. Collect 2 brushings (8-10 passes each) from the normal-appearing right main stem bronchus. Confirm your test order if bronchoscopy is inconclusive and your test results will be delivered within two weeks.